Last C$0.17 CAD
Change Today +0.04 / 30.77%
Volume 71.0K
SVA On Other Exchanges
Symbol
Exchange
Berlin
Venture
OTC US
As of 3:45 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

sernova corp (SVA) Snapshot

Open
C$0.13
Previous Close
C$0.13
Day High
C$0.17
Day Low
C$0.13
52 Week High
04/21/14 - C$0.34
52 Week Low
12/23/13 - C$0.12
Market Cap
22.4M
Average Volume 10 Days
34.0K
EPS TTM
--
Shares Outstanding
131.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SERNOVA CORP (SVA)

Related News

No related news articles were found.

sernova corp (SVA) Related Businessweek News

No Related Businessweek News Found

sernova corp (SVA) Details

Sernova Corp., a clinical-stage health sciences company, focuses on the development and commercialization of medical technologies. The company’s proprietary platform technologies include Cell Pouch System, a scalable device providing a natural organ-like environment for therapeutic cells, such as insulin producing islets for diabetics; and Sertolin, a cell-based technology providing an immune-privileged environment for donor cells, reducing or eliminating the need for anti-rejection drugs. It also intends to commercialize the products for parkinson’s, spinal cord injury, and haemophilia diseases. The company is headquartered in London, Canada.

sernova corp (SVA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$230.0K
Compensation as of Fiscal Year 2013.

sernova corp (SVA) Key Developments

Sernova Corp. Announces Advances Made in the Clinical Development of its Cell Pouch

Sernova Corp. provided a corporate update, summarizing advances made in the clinical development of its Cell Pouch over the past 12 months and the application of its technologies to new disease indications. The clinical assessment of the Cell Pouch in brittle diabetic patients with hypoglycemia unawareness who have received an islet transplant has shown in a small cohort of patients in interim analysis that the Cell Pouch is biocompatible and safe following implant and transplant. Safety is the primary endpoint of the study. Initial data from the study have shown the following three important findings: first, biocompatibility and a positive safety profile of the Cell Pouch have been shown in the first cohort of patients; second, the islets within the Cell Pouch, as shown by histological analysis, are well-vascularized, living within a natural tissue matrix and are able to make insulin, glucagon and somatostatin, key hormones in the control of blood glucose levels. The company believes such revascularization of islets and islet metabolic function within an implantable medical device for therapeutic cells in humans in this patient population is a first in the regenerative medicine field; third, these positive developments of the study suggest that Sernova's Cell Pouch may form a suitable environment for the survival and function of multiple types of therapeutic cells including human stem cells which can represent a virtually unlimited supply of cells for treating disease.

Sernova Corp. Presents at BIO International Convention, Jun-23-2014

Sernova Corp. Presents at BIO International Convention, Jun-23-2014 . Venue: San Diego Convention Center, San Diego, California, United States.

Kevin M. Egan Joins Sernova Corp. as Chair of Business Advisory Board

Sernova Corp. announced that Mr. Kevin M. Egan, President, Borealis Biotechnology LLC, has joined Sernova as Chair of the Business Advisory Board. Mr. Egan brings over 25 years of experience in biopharma, and commercialization & partnering expertise to the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVA:CN C$0.17 CAD +0.04

SVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVA.
View Industry Companies
 

Industry Analysis

SVA

Industry Average

Valuation SVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 4.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SERNOVA CORP, please visit www.sernova.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.